SurModics, Inc. (SRDX) said Friday that it has appointed Andy LaFrence as Vice President of Finance and Chief Financial Officer, effective February 12.
LaFrence will succeed Timothy Arens, who currently serves as interim Chief Financial Officer. Arens will remain with the company and will transition into the role of Vice President of Corporate Development and Strategy. In his new role, Arens will lead the company's efforts in developing strategies and assessing growth opportunities for its Medical Device and In Vitro Diagnostics businesses.
LaFrence has over 25 years of finance and management experience. Most recently, he served as Chief Financial Officer of CNS Therapeutics, which was recently acquired by Covidien. Prior to that, he was an audit partner at KPMG.
For comments and feedback: editorial@rttnews.com